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ABSTRACT
Methadone is commonly used for the treatment of pregnant opiate-addicts. But, it can have severe effects on the neonate
including Neonatal Abstinence Syndrome, increased length of stay in the neonatal intensive care unit, and intrauterine growth
retardation. Neonatal Abstinence Syndrome includes neurological excitability, gastrointestinal dysfunction, and autonomic signs.
Because of these adverse effects, studies have been conducted to determine what can help reduce the severe complications
caused by methadone. Varied dosages of methadone and alternative medications, such as buprenorphine, slow-release
morphine, and others have been studied. Most of the alternative medications, especially buprenorphine, are gaining popularity in
Europe where there is a growing problem of opiate use during pregnancy. In the studies comparing methadone and
buprenorphine, a slight decline in symptoms of Neonatal Abstinence Syndrome as well as shorter hospital stays for the neonates
exposed to buprenorphine was noted. Studies of different dosages of methadone were conducted to determine the lowest
methadone dose that is both effective for the mother and safe for the neonate. All of the studies have provided information that is
helping in the search for the safest and most effective treatment for opiate addiction. What is known is that helping the mother
overcome the addiction is very important. So far, the data collected are not strong enough to make a conclusion on the best
choice for treatment. Further research is indicated for methadone itself and also for all its possible alternatives.
INTRODUCTION
Use of illicit opiates, such as cocaine and heroin, in childbearing-age women is an increasing problem in many countries. 1 In the
United States, approximately 13% of pregnant women use illicit substances, and 19% of those women use opiate drugs. 2
Methadone has been used to treat opiate addiction during pregnancy since the 1970s. 3 Methadone, which crosses the placenta,
is well known to cause the fetus to become dependent on the drug. After birth, the neonate is likely to exhibit some degree of
withdrawal symptoms. Even though it is an opiate, methadone use to control opiate addiction during pregnancy does have
advantages over heroin, including longer gestational periods and higher birth weights as compared to untreated opiate-addicts. 4
Methadone, however, can cause a protracted and often severe Neonatal Abstinence Syndrome (NAS) as well as a prolonged
and extensive hospital stay in the special care nursery. 2 Fifty to ninety percent of neonates exposed to methadone and heroin will
develop withdrawal symptoms or NAS and up to fifty percent will require pharmacotherapy. 5 Methadone is important to help the
opiate-dependent mother abstain from using heroin or other drugs, but its use needs to be closely monitored by practitioners to
help achieve the best outcome for both mother and neonate.
Some degree of withdrawal occurs in all neonates whose mothers were treated with methadone. 3 NAS usually includes
neurological excitability, gastrointestinal dysfunction, and autonomic signs. Additional symptoms can include poor feeding, sleep© The Internet Journal of Allied Health Sciences and Practice, 2008
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wake abnormalities, vomiting, diarrhea, tachypnea, irritability, hyperphagia, dehydration, poor weight gain, and seizures.
Neonatal mortality, sudden infant death syndrome, and abnormal neurodevelopmental outcomes are also possible. 6
Methadone is a synthetic opioid with a long half-life that can provide the fetus with an environment for development that is not
subject to the fluctuations associated with NAS.7 Buprenorphine, an alternative approved for medical withdrawal and medicationassisted therapy, may be beneficial for treating opioid-dependency because of reduced neonatal withdrawal. 8 Buprenorphine is
an opioid partial agonist and is becoming increasingly used in the United Kingdom since being licensed in 1999. 9
There are several scoring systems used to determine NAS, including the Lipstiz, the Neonatal Abstinence Scoring, and the
Neonatal Withdrawal Inventory. These scoring systems provide more objective criteria for assessing neonates and determining
treatment.6 The onset of symptoms from heroin withdrawal tend to begin within 24 hours after birth, with clinical manifestations
initially being mild. Withdrawal from methadone begins between two to seven days after birth and can be delayed up to a month.
REVIEW OF THE LITERATURE
Thirteen studies are being compared to determine the effectiveness and safety of methadone compared to alternatives such as
buprenorphine.
______________________________________________________________________________________________________
Table 1. Comparison of Studies
Author

Purpose

# of Subjects

Fischer G, Ortner R,
Rohrmeister K,
Jagsch R, Baewert
A, Langer M, et al1

Comparing the
effects of methadone
directly to
buprenorphine in
both the mothers and
their neonates.

14 neonates and
mothers

Dashe J, Sheffield J,
Olscher D, Todd S,
Jackson G, Wendel
G. 3

Methadone doses
were reviewed
to determine if higher
doses caused an
increased risk of
NAS.

70 pregnant women

Lainwala S, Brown E,
Weinschenk N,
Blackwell M,
Hagadorn J. 5

Compare LOS of
infants treated for
NAS with
methadone,
compared to other
oral preparations.
Comparing the
transition from shortacting morphine to
buprenorphine or
methadone.

46 infants

Jones H, Johnson R,
Jasinski D, Milio L. 8

18 pregnant women
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Inclusion/Exclusion
Criteria
Inclusion: patient must be
opiate-dependent as
described by the DSM-IV,
older than 18 years,
provide an informed
consent, be HIV-negative,
and be between weeks 24
to 29 of pregnancy.
Exclusion: if they had
either severe somatic or
other severe psychiatric
diseases or a high-risk
pregnancy.
Inclusion: pregnant
women with opioid
addiction who delivered
live-born singletons of at
least 25 weeks’ gestation
between April 1, 1990 and
April 30, 2001. Exclusion:
if there was evidence of
fetal growth restriction or
oligohydramnios.

Study Design

Conclusions

Double-blind, doubledummy, randomized
control study

There was earlier
onset of NAS in
neonates born to the
methadone (mean 60
hours) than to the
buprenorphine groups
(mean 72 hours after
last medication)

Gestation =or > 36 weeks,
presence of NAS requiring
pharmacologic treatment,
in utero exposure to
methadone and/or
opiates.
Inclusion: patient must be
opiate-dependent as
described by the DSM-IV,
between 21 and 40 years
and between 16 and 30
weeks pregnant, provide
an informed consent, and
be HIV-negative.
Exclusion: if there was
polysubstance abuse as
well as either severe
somatic or other severe
psychiatric diseases or a

Retrospective Study

Inferential statistics,
c2, Fisher’s exact
tests, t-tests, and the
Mann-Whitney test
data.

Retrospective cohort
study
Chi-square, analysis
of variance, MantelHaenszel chi-square
for trend, Spearman
correlation coefficient
and Kruskal-Wallis.8

Chi-square and
Mann-Whitney tests.
Randomized
controlled study
Chi-square, log10
transformation to
stabilize variances,
univariate analysis of
variance, and MannWhitney test.

Maternal methadone
dosage was
associated with
duration of neonatal
hospitalization,
neonatal abstinence
score, and treatment
for withdrawal. Heroin
supplementation did
not alter this doseresponse relationship
Similar LOS in all
groups, but LOS
increased with higher
maternal methadone
or other opioid doses.
Significantly decreased
neonatal LOS for
buprenorphine
exposed neonates
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Lejeune C, SimmatDurand L, Gourarier
L, Aubisson S. 10

Compared the effects
of methadone directly
to buprenorphine in
both the mothers and
their neonates

260 neonates and
259 pregnant women

Methadone doses
were reviewed
to determine if higher
doses caused an
increased risk of
NAS.

81 pregnant women
and 81 neonates

Kuschel C,
Austerberry L,
Cornwell M, Couch
R, Rowley R. 12

Methadone doses
were reviewed
to determine if higher
doses caused an
increased risk of
NAS.

25 infants

Lacroix I, Berrebi A,
Chaumerliac C,
Lapeyre-Mestre M,
Montastruc J,
Damase-Michel C. 13

prospective follow-up
of 34 pregnant
women exposed to
buprenorphine
maintenance for
opiate dependence.
Compared the
neonatal abstinence
syndrome in
neonates of
methadone and
buprenorphine
maintained pregnant
opioid-dependent
women and to
provide preliminary
safety and efficacy
data for a larger
multi-center trial.
To show whether
hyperphagia was a
clinically significant
problem for the
infants whose mother
received methadone
treatment during
pregnancy.

McCarthy J, Leamon
M, Parr M, Anania B.
11

Jones H, Johnson R,
Jasinski D, O’Grady
K, Chisholm C, Choo
R, et al. 14

Martinez, A, Kastner,
B, Taeusch H. 17

high-risk pregnancy.
35 centers followed opioid
exposed neonates

3

Prospective
observational Study

Comparing methadone
with high dose
buprenorphine,
respectively, mean age
at the maximum Lipsitz
score was 81 h versus
66 h (P = 0.066).
High doses of
methadone not
associated with
increased risk for NAS

Inclusion: opiate
dependent mothers on
high dose methadone or
buprenorphine
Women were included if
they received the
treatment offered: trained
counseling, obstetric care,
written consent for
providers to
share information,
psychiatric assessment,
supportive psychotherapy,
and participate in a
weekly support group for
both pregnant and early
postpartum patients, and
random weekly urine drug
screens
Exclusion: 2 women left
treatment; 2 patients
requested to taper off
methadone, and 2
patients had
unavailable outcome
information.
Inclusion: approached at
antenatal visits by a
midwife affiliated to
ADAPT, and gave
informed consent for
participation in the study.
Exclusion: infants
delivered prematurely
at a gestation of less than
35 weeks.

Chi-square or
Fisher’s exact test, or
multivariate analysis

31 neonates

Women recruited from
drug treatment centers,
treated during pregnancy
with buprenorphine

Prospective Study

No significant
differences in
outcomes was
observed

14 pregnant women

Inclusion: opioiddependent pregnant
women and their
neonates in a
comprehensive drugtreatment facility that
included residential and
ambulatory care

Randomized, doubleblind, double-dummy,
flexible dosing,
parallel-group
controlled trial

There was earlier
onset of NAS in
neonates born to the
methadone (mean
60 hours) than to the
buprenorphine groups
(mean 72 hours

Retrospective Study
2-tailed t-tests,
chi-squared
analyses, and MannWhitney tests.

Prospective Study
Student’s t test or
Mann-Whitney U
test, x2 test.

Methadone
concentrations taken
from cord blood may
identify infants at
greater risk of neonatal
withdrawal and
therefore requiring
treatment.

Further study
warranted

44 neonates
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Inclusion: all infants born
at San Francisco General
Hospital to women
enrolled in a methadone
program during their
pregnancy as well as,
infants exposed to other
opiates
Exclusion: if the mother
used opiates but was not

Retrospective Study
SEM, ANOVA,
unpaired 2-tailed ttest, Wilcoxon Rank
Sum test,
Linear
regression analysis

Hyperphagia in the
neonatal period may
be a useful marker for
inadequate control of
NAS
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Lejeune C, Aubisson
S, Simmat-Durand L,
Cneude F, Piquet M.
18

Doberczak T, Kandall
S, Freidmann P. 19

Fischer G, Jagsch R,
Eder H, et al. 21

Compared the effects
of methadone directly
to buprenorphine in
both the mothers and
their neonates

246 neonates

To assess whether
there is a relationship
between neonatal
opiate withdrawal
and maternal
methadone usage,
maternal and
neonatal plasma
levels, or the rate of
decline of methadone
in neonatal plasma
Compared the effects
of methadone and
slow-releasing
morphine on NAS.

21 neonates

48 neonates and 48
pregnant women

enrolled in a methadone
program.
all neonates whose
mothers has been
maintained during
pregnancy on methadone
or high dose
buprenorphine were
included by 34 French
perinatal centers

Inclusion: drug-dependent
mothers with neonates
admitted to NICU where
they were observed for at
least 7days in an
enclosed incubator, and
then swaddled in
bassinets for continuing
care.
Inclusion: pregnant
women mean age, 26
years and mean
gestation, 22 weeks, who
were dependent on
opioids or
abused poly-substances
(mean duration, 61
months) and were willing
to follow the maintenance
program and to avoid
using illegal drugs

4

Prospective
multicentric study
Chi-square goodness
of fit test, Poisson
distribution and
regressions,
Estimation and test
of significance, and
Satterthwaite’s
method.
Prospective,
observational study
Standard deviation or
median, Spearman
rank correlation
coefficient .

Randomized,
unblended controlled
study
Finnegan score.
Other outcomes were
illegal
drug consumption
and nicotine
dependence

statistically significant
differences between
the groups were:
maintenance program
was more frequently
initiated before this
pregnancy for the
methadone vs.
buprenorphine group
(p<0.03);
careful reduction of the
maternal methadone
dosage during
pregnancy under
intensive medical and
psychosocial
surveillance may
benefit the drugexposed newborn
infant clinically
Neonates born to
mothers in the group
receiving methadone
and the group
receiving slow-release
morphine did not differ
in the duration of the
neonatal abstinence
syndrome (16 days in
the methadone group
vs 21 days in the slowrelease morphine
group; P=0.18).

Studies and Research Methods
Thirteen studies are presented that attempted to determine the effectiveness of methadone compared to alternatives such as
buprenorphine. The studies are relatively small and collectively suggest similar safety of buprenorphine as compared to
treatment with methadone in opiate addicted mothers and subsequent neonatal abstinence syndrome.
The studies vary widely in terms of design and research questions, limiting any collective judgements on outcomes. However,
they do appear to demonstrate the usefulness of buprenorphine as an alternative to methadone in the treatment of opiate
addicted mothers and neonates who develop NAS.
DISCUSSION
Methadone is a long-acting opioid that is similar to morphine and is commonly used to treat opioid dependence. Therefore, a
pregnant woman undergoing treatment for opioid dependence with methadone or alternative drugs to control her addiction
places her unborn child at risk for the development of complications after birth, especially NAS. 4 In the studies conducted,
methadone and an alternative drug, buprenorphine, were used to treat mothers during their pregnancies.
The trials noted above demonstrate that 30 to 50% of the methadone or buprenorphine exposed neonates developed NAS of a
severity that requires treatment of the neonate. 1,3,5,8,10,11,13,14 The length of stay (LOS) for methadone exposed neonates is harder
to determine and quite variable among the studies. According to Lainwala et al., the median LOS was 40 days, but in Kuschel et
al., the median LOS was only 15 days.5,12 The range of average LOS for neonates likely relates to a number of variables
including fetal maturity at delivery, availability of prenatal care, and dosage of methadone or buprenorphine required for
maintenance in the mother.
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The McCarthy et al. study compared mothers requiring high dose methadone to low dose methadone in order to determine if
dosage effected neonatal outcomes. 11 According to the study, there were no significant differences in the incidence of treated
NAS. However, higher doses of methadone prenatally had a positive effect on subsequent maternal drug abuse. In the Kuschel
study, cord blood was sampled from the neonate to determine if there is an increased risk of NAS with higher concentrations of
methadone.12 Maternal methadone dose had no effect on the risk of NAS. A lower dose might be more harmful than beneficial in
the neonate and mother by still causing NAS but not adequately treating the maternal drug dependence.
In the Doberczak et al. study, venous blood samples were collected from both mothers and their neonates within 24 hours of
birth.19 At 16 hours, the maternal plasma methadone level was 183 +/- 118 ng/ml and the neonatal level was 26+/-8 ng/ml. The
neonates had a rate of decrease of methadone in their plasma that averaged 0.2 +/- 0.3 ng/ml/hour. Of the 21 neonates, 17 had
moderate to severe NAS that required pharmacological treatment. They found that higher initial methadone levels were
associated with a more rapid decline of drug levels in the neonates. The rate of decrease in serum methadone levels correlated
with the acuity of the CNS withdrawal signs. Animal studies have shown that methadone accumulates in the non-human primate
brain. Exposure of the fetal brain to the opiates promotes regional development of specific opiate receptors and suppresses
neurotransmitter formation and function. Therefore, a more rapid decline in methadone levels can lead to an availability of opiate
receptors as well as replenishment of neurotransmitters. The increased sites and replenishment of neurotransmitters can
produce the neuronal excitability which clinically manifests as tremors, hyperreflexia and possibly seizures. The researchers
recommended reducing methadone dosages late in pregnancy to reduce the severity of neonatal withdrawal.
In the Fischer et al. study, slow-release morphine was compared to morphine. 21 The 48 women enrolled were split evenly with 24
in each group. There was no significant difference in the duration of NAS between the two groups (16 days in the methadone
group vs. 21 days for the slow-release morphine) or the doses they received. Also, the slow-release morphine did not reduce the
likelihood of developing NAS any more than the methadone.
Buprenorphine has increasingly been used as an alternative to methadone in the UK since being licensed there in 1999.9
Buprenorphine was tested in two studies. The Fischer et al. study showed that there is no significant difference between the two
treatments. The study was limited because of its small size. Three out of the six methadone babies developed NAS and three out
of eight buprenorphine babies developed it. However, in the methadone neonates, on average, they began treatment 12 hours
earlier (mean 60 hours, range 52-68) and their treatment lasted a mean duration of 5.3 days (range 4 to 7 days). 1 The
buprenorphine neonates began treatment at around 72 hours (range 35-109) and their duration of treatment lasted a mean of 4.8
days (range 1 to 8 days). During the treatment period, it was noted that the mothers on buprenorphine maintenance had a
considerable rate of additional consumption of opiates as compared to the methadone-treated group. The Lejeune studies were
the largest studies conducted.10,18 A total of 260 neonates were studied, with 101 neonates on methadone maintenance in utero
and 159 neonates on buprenorphine maintenance in utero. 10 Methadone and buprenorphine were compared on several
parameters including intrauterine growth retardation (IUGR) and length less than the 10 th percentile. Thirty-eight percent of the
methadone neonates compared to 31% of the buprenorphine neonates had IUGR. Fourth-six percent of the neonates on
methadone maintenance were less than the 10 th percentile in length compared to only 34% of buprenorphine neonates. The
mean birth weight was 2822g with 2790g mean for methadone and 2843g mean for buprenorphine. The mean Apgar score for
both methadone and buprenorphine were 9.9 and 9.8 respectively.
The second Lejeune et al. study included 246 women, 93 on methadone maintenance and 153 on high-dose buprenorphine. 18
There was no neonatal mortality with either drug. The only statistically significant differences between the methadone and highdose buprenorphine groups were that prematurity was 18% for the methadone group versus 9% for high-dose buprenorphine
group. Also, the mean age of the maximum Lipsitz score (measuring NAS symptoms) was hour 92 for the methadone group
compared to hour 70 for the high-dose buprenorphine group.
Jones et al. conducted a study comparing buprenorphine to methadone. 14 Although 30 women enrolled, only 20 completed the
study. Eleven women were treated with methadone and nine with buprenorphine during pregnancy. Of the 20 neonates, 20% of
buprenorphine-exposed and 45.5% of methadone-exposed neonates were treated for NAS. The amount of medication
administered to treat the NAS in the methadone-exposed neonates was three times greater than for the buprenorphine exposed
neonates. Buprenorphine exposed neonates remained in the hospital for a significantly shorter period of time (1.3 days
difference) than methadone-exposed neonates. Also, on average, buprenorphine-exposed neonates weighed 528 g more than
the methadone-exposed group and buprenorphine exposed neonates were discharged from the hospital 1.3 days earlier than
methadone-exposed neonates.
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In a review of this topic by Oei and Lui,16 the effects of drug abuse on neonates is assessed using various studies. In one study,
amphetamine usage was compared to methadone usages with 46% of amphetamine exposed infants developing significant NAS
compared to 80% methadone-exposed infants. They compare studies testing buprenorphine effects on neonates. The frequency
of severe NAS due to buprenorphine exposure appears to be variable and ranges from zero to around 50%. They also found that
the peak age at which symptoms of buprenorphine withdrawal occurs seems to be about the same time as withdrawal from
methadone, approximately 40 hours. However, peak NAS scores seem to occur later with buprenorphine at about 70 hours of
age. The authors also report that methadone withdrawal symptoms can first occur up 4 weeks after birth with subacute
symptoms lasting up to six months of age. Several studies were used to determine whether the dosage of methadone had an
effect on NAS. Studies were contradictory stating that both low and high doses may increase the severity of NAS. No definite
conclusions can be determined based on the studies they reviewed. However, they indicated that a rapid decline in the neonatal
methadone serum concentrations can increase the severity of the withdrawal symptoms. The neonates requiring
pharmacological treatment for NAS had an undetectable serum methadone level at 48 hours after birth.
In another review article by the “Committee on Drugs”, they also compare studies on dosage of maternal methadone. 20 Most
studies demonstrate that higher dosages later in pregnancy were associated with greater neonatal concentrations and an
increased risk for withdrawal. The larger dosages were associated with faster declines in neonatal serum concentrations and
more severe withdrawal in 21 infants. Several of the reviewed studies have found that there is a lower incidence and decreased
severity of NAS with lower maternal maintenance dosages, which is why some practitioners have recommended gradually
reducing the methadone dose prior to delivery.
Lacroix et al. compared several studies using buprenorphine maintenance. 13 Most of the studies are retrospective or include
neonates at birth; assessing for NAS. Eleven trials with a total of 244 neonates were studied and assessed. Of the 244 neonates,
32 were born with a form of withdrawal symptoms rated from mild to severe. Also, there were four premature neonates, six with
fetal growth retardation, three with fetal distress, and one with convulsions. The remaining 212 neonates were born without
complications being reported. The prospective studies were follow-ups of pregnant treated women and only evaluated small
numbers of women. Thirty-six neonates were assessed after birth, 13 had withdrawal complications with one premature neonate
and one with growth retardation. The remaining 23 neonates were healthy babies without complications.
Dashe et al.3 performed a retrospective cohort study comparing dosages of methadone. Women enrolled were started on 20mg
per day and adjusted accordingly as needed in 5mg intervals. After birth, the neonates were hospitalized for five to seven days
for observation. Neonatal abstinence scoring was used with a score exceeding 8 on two occasions, indicating the need for
treatment. Increasing the methadone dose was associated with lower birth weights below the tenth percentile, positive neonatal
toxicology screen for opioids, and positive screen for cocaine. Forty-six percent (46%) were treated for withdrawal, increasing
from 12% whose mothers received less than 20mg a day to 90% whose mothers received 40mg or more a day. Only three
neonates were treated for withdrawal symptoms of the 25 women who received less that 20mg a day. The higher the methadone
dose administered each day correlated to both a high neonatal abstinence score and a longer LOS.
The transplacental transfer of a drug may explain why there are differences in the severity of NAS. 15 Nanosvkaya et al. studied
the amount of buprenorphine transferred into the fetal circulation, its metabolism, and its effect on the tissue. An ex-vivo
technique of dual perfusion of placental lobule has proven to be a valuable tool for obtaining such information. According to the
study findings, “less than 10% of the buprenorphine was found in the fetal circulation, and the remainder was found in the tissue.”
The concentration ratios of the drug in tissue/maternal and tissue/fetal were 13 + 6.5 and 27.4 + 0.4. The drug sequestered did
not have any adverse effects on placental tissue viability and functional parameters. Less than 5% of the perfused buprenorphine
was metabolized to nor-buprenorphine during the 4 hours of perfusion and the metabolite was distributed between the tissue,
and maternal/fetal circulation. These data suggest that the therapeutic levels of buprenorphine in the maternal circulation may
have no indirect effects (via the placenta) on the fetus. The observed low transplacental transfer of buprenorphine to the fetal
circuit may explain the moderate/absence of neonatal withdrawal in the limited number of reports on mothers treated with the
drug during pregnancy.15
Methadone withdrawal symptoms not only occur in the first days of life, but also weeks or months after. Hyperphagia, described
as excessive oral intake greater than 190 cc/kg/day, is listed as one of many clinical findings in infants withdrawing from
opiates.17 In a study conducted by Martinez, Kastner, & Taeusch 17, hyperphagia is evaluated in 44 neonates exposed in utero to
methadone. The mean birth weight for the neonates was 2804g. By day 20, the neonates had reached a mean oral intake of 202
cc/kg/day. 26% were hyperphagic by day 8 with 56% hyperphagic by day 16. However, they found no correlation between the
oral intake and maternal methadone dose. Also they found that the median withdrawal score for the hyperphagic infants at day
28 was 12 compared with 5 for non-hyperphagic infants; there had been no differences before day 28. There was no increase in
© The Internet Journal of Allied Health Sciences and Practice, 2008
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gastrointestinal symptoms, vomiting, diarrhea, drooling, abdominal distention, or aspiration found between the hyperphagic
neonates and the non-hyperphagic neonates. Even though they found that neonates withdrawing from methadone were more
likely to become hyperphagic, there were few differences or complications.
There were limiting factors in many of the studies, such as finding a large enough sample size and participants that met the
inclusion criteria. However, in the studies compared, information gathered can be used to determine a good starting point. The
data collected indicates that methadone is helpful in the treatment of opiate addictions, but the effects on neonates can be
severe. Withdrawal symptoms are prevalent and seem to increase the LOS and complications. However, the complications start
in utero with IUGR and premature births. Compared to methadone, buprenorphine seems to offer some slight improvements.
Buprenorphine is shown to have NAS complications, as well as other complications in utero and at birth. However, the LOS for
buprenorphine-exposed neonates appeared to be shorter, with lesser degrees of NAS and a quicker recovery.
Another problem with the studies was controlling the other possible influences on neonatal outcomes. Smoking cigarettes is very
common during treatment, and the nicotine from the cigarettes has its own affects on the fetus. Therefore, it is hard to completely
determine which complications, such as IUGR, were the results of which substance. Further studies need to address and control
other substances used by the mothers. Buprenorphine seems to be an effective alternative to methadone, but future studies
would need to be conducted with larger populations.
CONCLUSIONS
Methadone is proven to have potential adverse effects on the neonate. 2,3,5,6 However, it is more appropriate for a pregnant
opiate-addict to obtain this treatment during her pregnancy rather than continuing heroin use. Methadone has been proven to
help opiate addicts, yet for pregnant opiate addicts, there must be concern for the effects on the unborn child. 3,4 This review
brought together several studies that attempted to assess the effects of methadone on the neonate. These studies have proven
inconclusive on the appropriate dosage that will benefit the mother yet keep the neonate safe. 3,11,19,20 As an alternative to
methadone, buprenorphine has proven effective in Europe for helping the mother as well as possibly lessening the effects on the
neonate.1,9,10,13,14,18 Case studies have been reassuring and rates of NAS were slightly reduced overall. Also, the severity and
duration of NAS seem to be improved.9 However, most studies conducted prove to be inconclusive about whether methadone
should be used or a new alternative such as buprenorphine should be seriously considered.
Since the population of opioid addicted mothers is rather small, it is hard to create large trials. An attempt to pool similar data
from across the country would provide the numbers needed to determine the best choices for the mother and the fetus or
neonate. The studies reviewed suggest that there may be some benefit from treatment with buprenorphine over methadone in
terms of less severity of NAS and shorter LOS, but the results are not clear enough to state conclusively that buprenorphine
should be used in place of methadone. For now, methadone seems to be an effective treatment as long as the mother also
receives the medical care she needs to have a healthy pregnancy with a healthy neonate.
Methadone can have many effects on neonates after birth, such as hyperphagia. Most symptoms tend to be limited to the first
few months of the neonates life. There are few studies that follow up on the children throughout their childhood to see if there are
long term effects. Hyperphagia appears to be a result of methadone withdrawal, and this may be a useful marker for sub-clinical
or impending NAS. Currently, the studies all conclude that methadone, buprenorphine, and other alternatives cause NAS, but
future studies are needed to determine what the long-term effects might be, if any.
It is important to remember that methadone treatment by itself cannot control all of the life issues associated with pregnancy and
heroin addiction. In addition to medications, the patient needs a comprehensive program which includes prenatal and medical
care, nutritional counseling, and attention to resolving their many medical, personal, and social problems. 7 A large, multi-dose
comparison of methadone and buprenorphine is needed to determine which is more appropriate in the treatment of opioidaddicted mothers and withdrawal-prone neonates.
______________________________________________________________________________________________________
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